Strategies to mitigate the occurrence of serious CRS and/or ICANS encompass administering low doses of CAR-T cells to patients with a high tumor burden and modifying the functional structure of CAR-T cells, since high tumor burden and CD28 costimulatory domain are risk factors associated with CAR-T cell-related toxicities [24]. The gene discussed is CD28; the disease is neoplasm.